The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis.
 
Sarah Verhoeff
No Relationships to Disclose
 
Suzanne C van Es
No Relationships to Disclose
 
Sjoerd G. Elias
No Relationships to Disclose
 
Sophie Gerritse
No Relationships to Disclose
 
Lindsay Angus
No Relationships to Disclose
 
Sjoukje Oosting
Research Funding - Celldex (Inst)
 
Sandra Heskamp
No Relationships to Disclose
 
Adrienne H. Brouwers
No Relationships to Disclose
 
Anne I.J. Arens
No Relationships to Disclose
 
Catharina Wilhelmina Menke
Consulting or Advisory Role - G1 Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - BMSi (Inst); Boehringer Ingelheim (Inst); Cristal Therapeutics (Inst); G1 Therapeutics (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche (Inst)
 
Otto S. Hoekstra
No Relationships to Disclose
 
Gerben J.C. Zwezerijnen
No Relationships to Disclose
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Peter Mulders
No Relationships to Disclose
 
Winette T.A. Van Der Graaf
Leadership - InHealth Group (I)
Honoraria - Bayer (I)
Consulting or Advisory Role - Bayer (I); Bayer (Inst); SpringWorks Therapeutics (Inst)
Speakers' Bureau - Bayer (I)
 
Elisabeth De Vries
Consulting or Advisory Role - Daiichi Sankyo (Inst); NSABP Foundation (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); CytomX Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Nordic Nanovector (Inst); Radius Health (Inst); Regeneron (Inst); Roche (Inst); Servier (Inst); Synthon (Inst)
(OPTIONAL) Uncompensated Relationships - ESMO (Inst); ESMO (Inst); RECIST Committee (Inst)
 
Wim J.G. Oyen
No Relationships to Disclose
 
Erik H.J.G. Aarntzen
No Relationships to Disclose
 
Carla M.L.- Van Herpen
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); MSD (Inst); Regeneron (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst)